Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1359 NTX-0471, engineered multivalent SIRPa and bispecific SIRPa-antiCCR4 molecules demonstrate superior activity providing path for mRNA expressed in-vivo biologics
Compose a Response to This Article
Other responses
No responses have been published for this article.